Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

Supplemental Table 2a. Unmatched and Propensity-matched Patient Characteristics (<65 years)

Variables	Unmatched Cohort			Propensity-matched Cohort		
	Surgical treatment (-) (n = 4,909)	Surgical treatment (+) (n = 2,894)	SMD	Surgical treatment (-) (n = 1,785)	Surgical treatment (+) (n = 1,785)	SMD
Age, years	51 [39-59]	51[41-59]	0.04	52 [40-59]	51 [41-59]	0.009
Male gender	3,384 (68.9%)	2,124 (73.4%)	0.099	1,284 (71.9%)	1,287 (72.1%)	0.004
BMI, kg/m^2						
<18.5 kg/m^2	845 (17.2%)	574 (19.8%)	0.068	336 (18.8%)	347 (19.4%)	0.016
18.5-24.9 kg/m^2	2,707 (55.1%)	1,686 (58.3%)	0.063	1,032 (57.8%)	1,032 (57.8%)	0.000
25.0-29.9 kg/m^2	769 (15.7%)	428 (14.8%)	-0.024	267 (15.0%)	259 (14.5%)	-0.013
≥30 kg/m^2	239 (4.9%)	92 (3.2%)	-0.086	61 (3.4%)	62 (3.5%)	0.003
Missing	349 (7.1%)	114 (3.9%)	-0.139	89 (5.0%)	85 (4.8%)	-0.010
Smoking	2,305 (47.0%)	1,536 (53.1%)	0.123	911 (51.0%)	908 (50.9%)	-0.003
Barthel Index						
Total dependence	668 (13.6%)	581 (20.1%)	0.173	281 (15.7%)	268 (15.0%)	-0.020
Severe dependence	143 (2.9%)	118 (4.1%)	0.063	64 (3.6%)	60 (3.4%)	-0.012
Moderate dependence	236 (4.8%)	140 (4.8%)	0.001	90 (5.0%)	87 (4.9%)	-0.008
Mild dependence	573 (11.7%)	317 (11.0%)	-0.023	196 (11.0%)	208 (11.7%)	0.021
Independence	2726 (55.5%)	1302 (45.0%)	-0.212	925 (51.8%)	935 (5.2%)	0.011
Missing	563 (11.5%)	436 (15.1%)	0.106	229 (12.8%)	227 (12.7%)	-0.003
JCS						
0 (alert)	4,254 (86.7%)	2,484 (85.8%)	-0.024	1,543 (86.4%)	1,540 (86.3%)	-0.005
1-3 (drowsy)	441 (9.0%)	269 (9.3%)	0.011	157 (8.8%)	156 (8.7%)	-0.002
10-30 (somnolence)	117 (2.4%)	79 (2.7%)	0.022	48 (2.7%)	50 (2.8%)	0.007

100-300 (coma)	97 (2.0%)	62 (2.1%)	0.012	37 (2.1%)	39 (2.2%)	0.008
Admission year						
2010	299 (6.1%)	178 (6.2%)	0.002	106 (5.9%)	109 (6.1%)	0.007
2011	562 (11.4%)	271 (9.4%)	-0.068	186 (10.4%)	174 (9.7%)	-0.022
2012	598 (12.2%)	378 (13.1%)	0.026	220 (12.3%)	222 (12.4%)	0.003
2013	613 (12.5%)	379 (13.1%)	0.018	253 (14.2%)	239 (13.4%)	-0.023
2014	696 (14.2%)	428 (14.8%)	0.017	268 (15.0%)	268 (15.0%)	0.000
2015	652 (13.3%)	386 (13.3%)	0.002	228 (12.8%)	233 (13.1%)	0.008
2016	695 (14.2%)	398 (13.8%)	-0.012	240 (13.4%)	244 (13.7%)	0.007
2017	700 (14.3%)	434 (15.0%)	0.021	260 (14.6%)	269 (15.1%)	0.014
2018	94 (1.9%)	42 (1.5%)	-0.036	24 (1.3%)	27 (1.5%)	0.014
Hospital Volume						
Low (<4)	176 (3.6%)	7 (0.2%)	-0.246	6 (0.3%)	7 (0.4%)	0.009
Middle (4≤ & <14)	916 (18.7%)	117 (4.0%)	-0.474	86 (4.8%)	104 (5.8%)	0.045
High (≥14)	3,817 (77.8%)	2,770 (95.7%)	0.549	1,693 (94.8%)	1,674 (93.8%)	-0.046
Clinical training hospital	4,157 (84.7%)	2,663 (92.0%)	0.230	1,632 (91.4%)	1,620 (90.8%)	-0.024
Emergent admission	3,603 (73.4%)	2,271 (78.5%)	0.119	1,341 (75.1%)	1,337 (74.9%)	-0.005
Comorbid conditions						
Hypertension	992 (20.2%)	705 (24.4%)	0.100	426 (23.9%)	420 (23.5%)	-0.008
Diabetes Mellitus	676 (13.8%)	392 (13.5%)	-0.007	227 (12.7%)	248 (13.9%)	0.035
Dyslipidemia	343 (7.0%)	194 (6.7%)	-0.011	143 (8.0%)	131 (7.3%)	-0.025
Atrial Fibrillation	248 (5.1%)	175 (6.0%)	0.043	106 (5.9%)	105 (5.9%)	-0.002
Malignancy	173(3.5%)	51 (1.8%)	-0.110	49 (2.7%)	42 (2.4%)	-0.025
Chronic Pulmonary Disease	135 (2.8%)	56 (1.9%)	-0.054	42 (2.4%)	43 (2.4%)	0.004
Chronic Liver Disease	266 (5.4%)	95 (3.3%)	-0.105	69 (3.9%)	65 (3.6%)	-0.012
Chronic Renal Disease	359(7.3%)	170 (5.9%)	-0.058	126 (7.1%)	122 (6.8%)	-0.009
In-hospital Complications						

Heart failure	1,212 (24.7%)	1,102 (38.1%)	0.292	577 (32.3%)	581 (32.5%)	0.005
- NYHA II	200 (4.1%)	185 (6.4%)	0.104	108 (6.1%)	109 (6.1%)	0.002
- NYHA III	114 (2.3%)	160 (5.5%)	0.166	73 (4.1%)	75 (4.2%)	0.006
- NYHA IV	81 (1.7%)	161 (5.6%)	0.211	56 (3.1%)	58 (3.2%)	0.006
Stroke	558 (11.4%)	513 (17.7%)	0.181	272 (15.2%)	265 (14.8%)	-0.011
Embolism	208 (4.2%)	183 (6.3%)	0.093	98 (5.5%)	93 (5.2%)	-0.012
Shock	45 (0.9%)	104 (3.6%)	0.181	35 (2.0%)	40 (2.2%)	0.020
DIC	151 (3.1%)	115 (4.0%)	0.049	55 (3.1%)	61 (3.4%)	0.019
Antibiotics for more than 2 weeks						
Penicillin system	1,781 (36.3%)	1,583 (54.7%)	0.376	934 (52.3%)	922 (51.7%)	-0.013
Cephem system	1,282 (26.1%)	1,207 (41.7%)	0.334	659 (36.9%)	654 (36.6%)	-0.006
Carbapenem	260 (5.3%)	340 (11.7%)	0.233	163 (9.1%)	152 (8.5%)	-0.022
Aminoglycoside	1,512 (30.8%)	1,449 (50.1%)	0.400	855 (47.9%)	849 (47.6%)	-0.007
Glycopeptide	541 (11.0%)	696 (24.0%)	0.348	335 (18.8%)	326 (18.3%)	-0.013
Daptomycin	130 (2.6%)	145 (5.0%)	0.123	73 (4.1%)	70 (3.9%)	-0.009
Linezolid	49 (1.0%)	93 (3.2%)	0.155	39 (2.2%)	40 (2.2%)	0.004
Antifungal antibiotics	46 (0.9%)	85 (2.9%)	0.145	33 (1.8%)	30 (1.7%)	-0.013
Intensive Treatment within 2 days after admission						
Admission to HCU	148 (3.0%)	118 (4.1%)	0.057	67 (3.8%)	64 (3.6%)	-0.009
Admission to ICU	317 (6.5%)	938 (32.4%)	0.694	251 (14.1%)	227 (12.7%)	-0.039
Inotropic therapy	336 (6.8%)	900(31.1%)	0.650	234 (13.1%)	207 (11.6%)	-0.046
Ventilation Support	203 (4.1%)	551 (19.0%)	0.479	139 (7.8%)	129 (7.2%)	-0.021
CRRT	49 (1.0%)	86 (3.0%)	0.142	35 (2.0%)	34 (1.9%)	-0.004
IRRT	247 (5.0%)	101 (3.5%)	-0.076	82 (4.6%)	74 (4.1%)	-0.022
PMX-DHP	17 (0.3%)	19 (0.7%)	0.044	9 (0.5%)	8 (0.4%)	-0.008

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Open Heart

Data are expressed as the median [interquartile range] or number (percentage). SMD, standardized mean difference; BMI, Body mass index; JCS, Japan Coma Scale; NYHA, New York Heart Association; DIC, Disseminated intravascular coagulation; HCU, high care unit; ICU, intensive care unit; CRRT, continuous renal replacement therapy; IRRT, intermittent renal replacement therapy; PMX-DHP, Polymyxin B-immobilized fiber column-direct hemoperfusion.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Open Heart

Supplemental Table 2b. Unmatched and Propensity-matched Patient Characteristics (65 to 79 years)

Variables	Unmatched Cohort			Propensity-matched Cohort		
	Surgical treatment (-) (n = 5,628)	Surgical treatment (+) (n = 2,246)	SMD	Surgical treatment (-) (n = 1,625)	Surgical treatment (+) (n = 1,625)	SMD
Age, years	73 [69-76]	71 [68-75]	-0.209	72 [68-75]	72 [68-75]	-0.005
Male gender	3,440(61.1%)	1,459(65.0%)	0.080	1038 (63.9%)	1,043 (64.2%)	0.006
BMI, kg/m^2						
<18.5 kg/m^2	957 (17.0%)	397 (17.7%)	0.018	280 (17.2%)	274 (16.9%)	-0.010
18.5-24.9 kg/m^2	3,296 (58.6%)	1,382 (61.5%)	0.061	999 (61.5%)	985 (60.6%)	-0.018
25.0-29.9 kg/m^2	761 (13.5%)	298 (13.3%)	-0.007	226 (13.9%)	228 (14%)	0.004
≥30 kg/m^2	147 (2.6%)	66 (2.9%)	0.020	43 (2.6%)	52 (3.2%)	0.033
Missing	467 (8.3%)	103 (4.6%)	-0.152	77 (4.7%)	86 (5.3%)	0.025
Smoking	2,312(41.1%)	977 (43.5%)	0.049	696 (42.8%)	706 (43.4%)	0.012
Barthel Index						
Total dependence	1,335 (23.7%)	565 (25.2%)	0.033	362 (22.3%)	366 (22.5%)	0.006
Severe dependence	266 (4.7%)	107 (4.8%)	0.002	78 (4.8%)	75 (4.6%)	-0.009
Moderate dependence	430 (7.6%)	159 (7.1%)	-0.021	131(8.1%)	124 (7.6%)	-0.016
Mild dependence	656 (11.7%)	200 (8.9%)	-0.091	156 (9.6%)	156 (9.6%)	0.000
Independence	1996 (35.5%)	772 (34.4%)	-0.023	593 (36.5%)	608 (37.4%)	0.019
Missing	945 (16.8%)	443 (19.7%)	0.076	305 (18.8%)	296 (18.2%)	-0.014
JCS						
0 (alert)	4,473 (79.5%)	1,868 (83.2%)	0.095	1,378 (84.8%)	1,357 (83.5%)	-0.035
1-3 (drowsy)	783 (13.9%)	275 (12.2%)	-0.050	179 (11%)	189 (11.6%)	0.019
10-30 (somnolence)	228 (4.1%)	56 (2.5%)	-0.088	40 (2.5%)	45 (2.8%)	0.019
100-300 (coma)	144 (2.6%)	47 (2.1%)	-0.031	28 (1.7%)	34 (2.1%)	0.027

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

Admission year						
2010	317 (5.6%)	115 (5.1%)	-0.023	90 (5.5%)	80 (4.9%)	-0.028
2011	585 (10.4%)	152 (6.8%)	-0.130	123 (7.6%)	123 (7.6%)	0.000
2012	646 (11.5%)	273 (12.2%)	0.021	193 (11.9%)	194 (11.9%)	0.002
2013	631 (11.2%)	278 (12.4%)	0.036	199 (12.2%)	199 (12.2%)	0.000
2014	738 (13.1%)	331 (14.7%)	0.047	226 (13.9%)	239 (14.7%)	0.023
2015	826 (14.7%)	327 (14.6%)	-0.003	216 (13.3%)	223 (13.7%)	0.013
2016	894 (15.9%)	363 (16.2%)	0.008	274 (16.9%)	262 (16.1%)	-0.020
2017	863 (15.3%)	373 (16.6%)	0.035	274 (16.9%)	277 (17%)	0.005
2018	128 (2.3%)	34 (1.5%)	-0.056	30 (1.8%)	28 (1.7%)	-0.009
Hospital Volume						
Low (<4)	254 (4.5%)	2 (0.1%)	-0.298	2 (0.1%)	2 (0.1%)	0.000
Middle (4≤ & <14)	1,097 (19.5%)	116 (5.2%)	-0.447	93 (5.7%)	111 (6.8%)	0.046
High (≥14)	4,277 (76.0%)	2,128 (94.7%)	0.550	1,530 (94.2%)	1,512 (93%)	-0.045
Clinical training hospital	4,613 (82.0%)	2,028 (90.3%)	0.243	1,435 (88.3%)	1,441 (88.7%)	0.012
Emergent admission	4,382 (77.9%)	1,781 (79.3%)	0.035	1,251 (77%)	1,259 (77.5%)	0.012
Comorbid conditions						
Hypertension	1,671 (29.7%)	670 (29.8%)	0.003	500 (30.8%)	500 (30.8%)	0.000
Diabetes Mellitus	1,250 (22.2%)	416 (18.5%)	-0.092	309 (19%)	323 (19.9%)	0.022
Dyslipidemia	571 (10.1%)	197 (8.8%)	-0.047	166 (10.2%)	164 (10.1%)	-0.004
Atrial Fibrillation	731 (13.0%)	300 (13.4%)	0.011	211 (13.0%)	219(13.5%)	0.015
Malignancy	503 (8.9%)	113 (5.0%)	-0.154	96 (5.9%)	95 (5.8%)	-0.003
Chronic Pulmonary Disease	211 (3.7%)	47 (2.1%)	-0.098	47 (2.9%)	40 (2.5%)	-0.027
Chronic Liver Disease	263 (4.7%)	64 (2.8%)	-0.096	50 (3.1%)	50 (3.1%)	0.000
Chronic Renal Disease	727 (12.9%)	227 (10.1%)	-0.088	173 (10.6%)	171 (10.5%)	-0.004
In-hospital Complications						
Heart failure	1,722 (30.6%)	996 (44.3%)	0.287	666 (41%)	669 (41.2%)	0.004

- NYHA II	283 (5.0%)	137 (6.1%)	0.047	100 (6.2%)	94 (5.8%)	-0.016
- NYHA III	179 (3.2%)	140 (6.2%)	0.145	86 (5.3%)	85 (5.2%)	-0.003
- NYHA IV	144 (2.6%)	125 (5.6%)	0.153	75 (4.6%)	67 (4.1%)	-0.024
Stroke	686 (12.2%)	325 (14.5%)	0.067	220 (13.5%)	219 (13.5%)	-0.002
Embolism	152 (2.7%)	65 (2.9%)	0.012	52 (3.2%)	46 (2.8%)	-0.022
Shock	57 (1.0%)	84 (3.7%)	0.180	33 (2%)	37 (2.3%)	0.017
DIC	176 (3.1%)	101 (4.5%)	0.072	56 (3.4%)	59 (3.6%)	0.010
Antibiotics for more than 2 weeks						
Penicillin system	1,953 (34.7%)	1,224 (54.5%)	0.406	874 (53.8%)	853 (52.5%)	-0.026
Cephem system	1,383 (24.6%)	819 (36.5%)	0.260	564 (34.7%)	545 (33.5%)	-0.025
Carbapenem	349 (6.2%)	338 (15.0%)	0.290	167 (10.3%)	179 (11%)	0.024
Aminoglycoside	1,496 (26.6%)	972 (43.3%)	0.356	696 (42.8%)	666 (41%)	-0.037
Glycopeptide	776 (13.8%)	676 (30.1%)	0.402	405 (24.9%)	393 (24.2%)	-0.017
Daptomycin	152 (2.7%)	146 (6.5%)	0.182	88 (5.4%)	81 (5.0%)	-0.019
Linezolid	39 (0.7%)	80 (3.6%)	0.200	28 (1.7%)	27 (1.7%)	-0.005
Antifungal antibiotics	93 (1.7%)	144 (6.4%)	0.244	55 (3.4%)	59 (3.6%)	0.013
Intensive Treatment within 2 days after admission						
Admission to HCU	209 (3.7%)	96 (4.3%)	0.029	68 (4.2%)	67 (4.1%)	-0.003
Admission to ICU	410 (7.3%)	645 (28.7%)	0.581	248 (15.3%)	248 (15.3%)	0.000
Inotropic therapy	499 (8.9%)	706 (31.4%)	0.586	293 (18%)	289 (17.8%)	-0.006
Ventilation Support	267 (4.7%)	407 (18.1%)	0.430	141 (8.7%)	151 (9.3%)	0.022
CRRT	91 (1.6%)	84 (3.7%)	0.132	37 (2.3%)	42 (2.6%)	0.020
IRRT	386 (6.9%)	112 (5.0%)	-0.079	96 (5.9%)	91 (5.6%)	-0.013
PMX-DHP	16 (0.3%)	13 (0.6%)	0.045	5 (0.3%)	4 (0.2%)	-0.012

Data are expressed as the median [interquartile range] or number (percentage). SMD, standardized mean difference; BMI, Body mass index;

JCS, Japan Coma Scale; NYHA, New York Heart Association; DIC, Disseminated intravascular coagulation; HCU, high care unit; ICU,

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

intensive care unit; CRRT, continuous renal replacement therapy; IRRT, intermittent renal replacement therapy; PMX-DHP, Polymyxin B-immobilized fiber column-direct hemoperfusion.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

Supplemental Table 2c. Unmatched and Propensity-matched Patient Characteristics (≥80 years)

Variables	Unmatched Cohort			Propensity-matched Cohort		
	Surgical treatment (-) (n = 4,525)	Surgical treatment (+) (n = 465)	SMD	Surgical treatment (-) (n = 414)	Surgical treatment (+) (n = 414)	SMD
Age, years	85 [82-88]	82 [81-84]	-0.825	82 [81-84]	82 [81-84]	0.046
Male Gender	2,568 (56.8%)	226 (48.6%)	-0.164	211 (51.0%)	209 (50.5%)	-0.010
BMI, kg/m^2						
<18.5 kg/m^2	1,081 (23.9%)	90 (19.4%)	-0.110	78 (18.8%)	83 (20.0%)	0.031
18.5-24.9 kg/m^2	2,354 (52.0%)	303 (65.2%)	0.269	275 (66.4%)	265 (64.0%)	-0.051
25.0-29.9 kg/m^2	414 (9.1%)	49 (10.5%)	0.047	39 (9.4%)	45 (10.9%)	0.048
≥30 kg/m^2	67 (1.5%)	9 (1.9%)	0.035	6 (1.4%)	7 (1.7%)	0.019
Missing	609 (13.5%)	14 (3.0%)	-0.387	16 (3.9%)	14 (3.4%)	-0.026
Smoking	1,316 (29.1%)	179 (38.5%)	0.200	158 (38.2%)	155 (37.4%)	-0.015
Barthel Index						
Total dependence	1,832 (40.5%)	135 (29.0%)	-0.242	111 (26.8%)	118 (28.5%)	0.038
Severe dependence	285 (6.3%)	25 (5.4%)	-0.039	16 (3.9%)	23 (5.6%)	0.080
Moderate dependence	432 (9.5%)	41 (8.8%)	-0.025	30 (7.2%)	37 (8.9%)	0.062
Mild dependence	470 (10.4%)	52 (11.2%)	0.026	52 (12.6%)	47 (11.4%)	-0.037
Independence	722 (16.0%)	126 (27.1%)	0.274	121 (29.2%)	111 (26.8%)	-0.054
Missing	784 (17.3%)	86 (18.5%)	0.030	84 (20.3%)	78 (18.8%)	-0.037
JCS						
0 (alert)	2,990 (66.1%)	368 (79.1%)	0.296	337 (81.4%)	325 (78.5%)	-0.072
1-3 (drowsy)	1,086 (24.0%)	70 (15.1%)	-0.227	59 (14.3%)	67 (16.2%)	0.054
10-30 (somnolence)	301 (6.7%)	17 (3.7%)	-0.136	11 (2.7%)	14 (3.4%)	0.042
100-300 (coma)	148 (3.3%)	10 (2.2%)	-0.069	7 (1.7%)	8 (1.9%)	0.018

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

Admission year						
2010	191 (4.2%)	23 (4.9%)	0.035	19 (4.6%)	20 (4.8%)	0.011
2011	467 (10.3%)	23 (4.9%)	-0.203	20 (4.8%)	22 (5.3%)	0.022
2012	470 (10.4%)	47 (10.1%)	-0.009	44 (10.6%)	45 (10.9%)	0.008
2013	445 (9.8%)	55 (11.8%)	0.064	51 (12.3%)	52 (12.6%)	0.007
2014	621 (13.7%)	65 (14.0%)	0.007	49 (11.8%)	56 (13.5%)	0.051
2015	604 (13.3%)	81 (17.4%)	0.113	73 (17.6%)	70 (16.9%)	-0.019
2016	794 (17.5%)	80 (17.2%)	-0.009	68 (16.4%)	67 (16.2%)	-0.007
2017	817 (18.1%)	81 (17.4%)	-0.017	82 (19.8%)	74 (17.9%)	-0.049
2018	116 (2.6%)	10 (2.2%)	-0.027	8 (1.9%)	8 (1.9%)	0.000
Hospital Volume						
Low (<4)	282 (6.2%)	0 (0.0%)	-0.365	0 (0.0%)	0 (0.0%)	0.000
Middle (4≤ & <14)	1,116 (24.7%)	23 (4.9%)	-0.578	19 (4.6%)	22 (5.3%)	0.033
High (≥14)	3,127 (69.1%)	442 (95.1%)	0.719	395 (95.4%)	392 (94.7%)	-0.033
Clinical training hospital	3,644 (80.5%)	399 (85.8%)	0.141	354 (85.5%)	358 (86.5%)	0.028
Emergent admission	3,894 (86.1%)	372 (80.0%)	-0.162	321 (77.5%)	330 (79.7%)	0.053
Comorbid conditions						
Hypertension	1,439 (31.8%)	149 (32.0%)	0.005	129 (31.2%)	133 (32.1%)	0.021
Diabetes Mellitus	711 (15.7%)	80 (17.2%)	0.040	55 (13.3%)	64 (15.5%)	0.062
Dyslipidemia	386 (8.5%)	51 (11.0%)	0.082	42 (10.1%)	42 (10.1%)	0.000
Atrial Fibrillation	637 (14.1%)	61 (13.1%)	-0.028	52 (12.6%)	52 (12.6%)	0.000
Malignancy	365 (8.1%)	32 (6.9%)	-0.045	35 (8.5%)	29 (7%)	-0.054
Chronic Pulmonary Disease	197 (4.4%)	13 (2.8%)	-0.084	16 (3.9%)	13 (3.1%)	-0.039
Chronic Liver Disease	130 (2.9%)	22 (4.7%)	0.097	18 (4.3%)	19 (4.6%)	0.012
Chronic Renal Disease	428 (9.5%)	43 (9.2%)	-0.007	51 (12.3%)	40 (9.7%)	-0.085
In-hospital Complications						
Heart failure	1,779 (39.3%)	205 (44.1%)	0.097	187 (45.2%)	184 (44.4%)	-0.015

- NYHA II	182 (4.0%)	24 (5.2%)	0.054	20 (4.8%)	23 (5.6%)	0.033
- NYHA III	153 (3.4%)	23 (4.9%)	0.078	21 (5.1%)	21 (5.1%)	0.000
- NYHA IV	166 (3.7%)	36 (7.7%)	0.176	29 (7%)	31 (7.5%)	0.019
Stroke	481 (10.6%)	61 (13.1%)	0.077	44 (10.6%)	52 (12.6%)	0.060
Embolism	89 (2.0%)	7 (1.5%)	-0.035	6 (1.4%)	7 (1.7%)	0.019
Shock	53 (1.2%)	20 (4.3%)	0.193	14 (3.4%)	18 (4.3%)	0.050
DIC	154 (3.4%)	22 (4.7%)	0.067	20 (4.8%)	20 (4.8%)	0.000
Antibiotics for more than 2 weeks						
Penicillin system	1,517 (33.5%)	213 (45.8%)	0.253	186 (44.9%)	187 (45.2%)	0.005
Cephem system	1,178 (26.0%)	178 (38.3%)	0.264	164 (39.6%)	155 (37.4%)	-0.045
Carbapenem	378 (8.4%)	80 (17.2%)	0.267	59 (14.3%)	66 (15.9%)	0.047
Aminoglycoside	979 (21.6%)	174 (37.4%)	0.351	142 (34.3%)	147 (35.5%)	0.025
Glycopeptide	622 (13.7%)	161 (34.6%)	0.502	129 (31.2%)	134 (32.4%)	0.026
Daptomycin	101 (2.2%)	29 (6.2%)	0.200	26 (6.3%)	25 (6.0%)	-0.010
Linezolid	31 (0.7%)	14 (3.0%)	0.173	7 (1.7%)	8 (1.9%)	0.018
Antifungal antibiotics	70 (1.5%)	32 (6.9%)	0.268	23 (5.6%)	21 (5.1%)	-0.022
Intensive Treatment within 2 days after admission						
Admission to HCU	162 (3.6%)	16 (3.4%)	-0.008	18 (4.3%)	15 (3.6%)	-0.037
Admission to ICU	219 (4.8%)	128 (27.5%)	0.647	81 (19.6%)	83 (20%)	0.012
Inotropic therapy	369 (8.2%)	131 (28.2%)	0.537	87 (21%)	90 (21.7%)	0.018
Ventilation Support	153 (3.4%)	84 (18.1%)	0.488	48 (11.6%)	48 (11.6%)	0.000
CRRT	30 (0.7%)	19 (4.1%)	0.226	17 (4.1%)	15 (3.6%)	-0.025
IRRT	128 (2.8%)	17 (3.7%)	0.047	19 (4.6%)	15 (3.6%)	-0.049
PMX-DHP	6 (0.1%)	1 (0.2%)	0.020	2 (0.5%)	1 (0.2%)	-0.040

Data are expressed as the median [interquartile range] or number (percentage). SMD, standardized mean difference; BMI, Body mass index; JCS, Japan Coma Scale; NYHA, New York Heart Association; DIC, Disseminated intravascular coagulation; HCU, high care unit; ICU,

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

intensive care unit; CRRT, continuous renal replacement therapy; IRRT, intermittent renal replacement therapy; PMX-DHP, Polymyxin B-immobilized fiber column-direct hemoperfusion.